echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The anti-PD-1 monoclonal antibody drug "Paampril" showed excellent results in the mid-term clinical trial of phase III

    The anti-PD-1 monoclonal antibody drug "Paampril" showed excellent results in the mid-term clinical trial of phase III

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    China Biopharmaceutical Co.


    Currently, lung cancer is the number one malignant tumor in China in terms of morbidity and mortality.


    The Fc receptor and complement-mediated utility of Paampril are completely eliminated by mutations in the Fc region.


    Paimrizumab was jointly developed and commercialized by a joint venture established by Kangfang Biological and China Biopharmaceutical Co.


    Stomach cancer

    State Drug Administration Bureau in May 2020 accepted to send Puli monoclonal antibody for the treatment after at least a second-line systemic chemotherapy relapsed or refractory classical Hodgkin lymphoma (r / rcHL) of the New Drug Application.


    Manage lymphoma leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.